While viral transduction, electroporation, microinjection and lipofection or are gold standards in most of CRISPR-Cas9 protocols, there is little consideration for alternative chemical tools. However, polymer-based nanoparticles like the Viromer® reagents have the potential for high performance transfection among various cell types, including some hard-to-transfect cells, with low impact on cell physiology or cell viability.
At Lipocalyx, we have listened to researchers looking for other solutions. While our bestseller reagent, the Viromer® RED, has proven great efficiency for transfecting CRISPR plasmids or Cas9-mRNA, it gave a low output when tested for Cas9/gRNA RNP complex delivery. We therefore screened again over the Viromer® library and worked on formulation to select the best of our technology for that specific purpose.
Based on a collaborative work with OriGene (USA) who provided all CRISPR components for knocking-out RFP expression in stable HEK cells, we first identified two candidates with the required efficiency and outperforming the main leading competitor (lipofection-based reagent).